These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


423 related items for PubMed ID: 24519517

  • 21. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
    Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.
    Clin Cancer Res; 2019 Mar 15; 25(6):1809-1816. PubMed ID: 30514777
    [Abstract] [Full Text] [Related]

  • 22. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H, Wang S, Song C, Zha Y, Li L.
    World J Surg Oncol; 2016 Oct 12; 14(1):261. PubMed ID: 27733166
    [Abstract] [Full Text] [Related]

  • 23. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.
    PLoS One; 2011 Feb 18; 6(2):e17156. PubMed ID: 21365007
    [Abstract] [Full Text] [Related]

  • 24. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
    Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR, Sanadhya D, Shah ZA, Naikoo NA.
    Sci Rep; 2018 Apr 30; 8(1):6704. PubMed ID: 29712977
    [Abstract] [Full Text] [Related]

  • 25. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW.
    J Neurol; 2017 Feb 30; 264(2):350-358. PubMed ID: 27921166
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
    Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.
    Int J Mol Sci; 2012 Feb 30; 13(6):6983-6994. PubMed ID: 22837675
    [Abstract] [Full Text] [Related]

  • 28. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.
    Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, Wang Y.
    Cancer Biol Med; 2021 Feb 15; 18(1):272-282. PubMed ID: 33628600
    [Abstract] [Full Text] [Related]

  • 29. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
    Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F.
    Childs Nerv Syst; 2010 Aug 15; 26(8):1051-6. PubMed ID: 20552207
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.
    J Clin Oncol; 2008 May 01; 26(13):2192-7. PubMed ID: 18445844
    [Abstract] [Full Text] [Related]

  • 34. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
    Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA, Lind GE.
    J Transl Med; 2012 Mar 06; 10():36. PubMed ID: 22390413
    [Abstract] [Full Text] [Related]

  • 35. The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma.
    Jovanović N, Mitrović T, Cvetković VJ, Tošić S, Vitorović J, Stamenković S, Nikolov V, Kostić A, Vidović N, Krstić M, Jevtović-Stoimenov T, Pavlović D.
    Medicina (Kaunas); 2019 Feb 01; 55(2):. PubMed ID: 30717206
    [Abstract] [Full Text] [Related]

  • 36. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 37. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G.
    Eur J Cancer; 2021 Apr 10; 147():84-94. PubMed ID: 33631540
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ.
    Neurosurgery; 2009 Nov 10; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 22.